Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Idiopathic venous thromboembolic disease is associated with a poorer prognosis from subsequent malignancy.

Jones A, Stockton DL, Simpson AJ, Murchison JT.

Br J Cancer. 2009 Sep 1;101(5):840-2. doi: 10.1038/sj.bjc.6605210. Epub 2009 Aug 4.

2.

Postoperative venous thromboembolism predicts survival in cancer patients.

Auer RA, Scheer AS, McSparron JI, Schulman AR, Tuorto S, Doucette S, Gonsalves J, Fong Y.

Ann Surg. 2012 May;255(5):963-70. doi: 10.1097/SLA.0b013e31824daccb.

PMID:
22504195
3.

Is extensive screening for cancer in idiopathic venous thromboembolism warranted?

Van Doormaal FF, Terpstra W, Van Der Griend R, Prins MH, Nijziel MR, Van De Ree MA, Büller HR, Dutilh JC, ten Cate-Hoek A, Van Den Heiligenberg SM, Van Der Meer J, Otten JM.

J Thromb Haemost. 2011 Jan;9(1):79-84. doi: 10.1111/j.1538-7836.2010.04101.x.

4.

A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system.

Yu YB, Gau JP, Liu CY, Yang MH, Chiang SC, Hsu HC, Hong YC, Hsiao LT, Liu JH, Chiou TJ, Chen PM, Lee TS, Chou LF, Tzeng CH, Chen TJ.

Thromb Haemost. 2012 Aug;108(2):225-35. doi: 10.1160/TH12-01-0010. Epub 2012 Apr 26.

PMID:
22534880
5.

Clinical outcomes and factors predicting development of venous thromboembolic complications in patients with advanced refractory cancer in a Phase I Clinic: the M. D. Anderson Cancer Center experience.

Vemulapalli S, Chintala L, Tsimberidou AM, Dhillon N, Lei X, Hong D, Kurzrock R.

Am J Hematol. 2009 Jul;84(7):408-13. doi: 10.1002/ajh.21423.

6.

Venous thromboembolism (VTE) in patients with advanced gastric cancer: an Asian experience.

Kang MJ, Ryoo BY, Ryu MH, Koo DH, Chang HM, Lee JL, Kim TW, Kang YK.

Eur J Cancer. 2012 Mar;48(4):492-500. doi: 10.1016/j.ejca.2011.11.016. Epub 2011 Dec 12.

PMID:
22169121
7.

[Cancer in patients with venous thromboembolic disease].

Calvo Romero JM, Lima Rodríguez EM.

An Med Interna. 2007 Dec;24(12):571-3. Spanish.

PMID:
18278993
8.

Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States.

Khorana AA, Dalal M, Lin J, Connolly GC.

Cancer. 2013 Feb 1;119(3):648-55. doi: 10.1002/cncr.27772. Epub 2012 Aug 14.

9.

Long-term survival of patients with a history of venous thromboembolism.

Reitter SE, Waldhoer T, Mayerhofer M, Eigenbauer E, Ay C, Kyrle PA, Pabinger I.

Ann Hematol. 2011 May;90(5):585-94. doi: 10.1007/s00277-011-1160-0. Epub 2011 Feb 2.

PMID:
21287349
10.

Treatment of venous thromboembolism in cancer patients.

Lee AY.

Best Pract Res Clin Haematol. 2009 Mar;22(1):93-101. doi: 10.1016/j.beha.2008.11.001. Review.

PMID:
19285276
11.

Limited malignancy screening of patients with idiopathic venous thromboembolism.

Semb VB, Tveit A.

Tidsskr Nor Laegeforen. 2014 Feb 25;134(4):407-11. doi: 10.4045/tidsskr.13.0310. English, Norwegian.

12.

Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study.

Tetsche MS, Nørgaard M, Pedersen L, Lash TL, Sørensen HT.

BMC Cancer. 2006 Jul 17;6:189.

13.

High D-dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes.

Paneesha S, Cheyne E, French K, Bacchu S, Borg A, Rose P.

Br J Haematol. 2006 Oct;135(1):85-90. Epub 2006 Aug 22.

PMID:
16925794
14.

Venous thromboembolism in patients with cholangiocarcinoma: focus on risk factors and impact on survival.

Jeon HK, Kim DU, Baek DH, Ha DW, Lee BE, Ryu DY, Cheong JH, Kim GH, Song GA, Jang AL.

Eur J Gastroenterol Hepatol. 2012 Apr;24(4):444-9. doi: 10.1097/MEG.0b013e328350f93c.

PMID:
22410715
15.

Symptomatic and incidental venous thromboembolic disease are both associated with mortality in patients with prostate cancer.

Chaturvedi S, Sidana S, Elson P, Khorana AA, McCrae KR.

PLoS One. 2014 Aug 15;9(8):e94048. doi: 10.1371/journal.pone.0094048. eCollection 2014.

16.

Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients.

Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY.

J Thromb Haemost. 2009 May;7(5):760-5. doi: 10.1111/j.1538-7836.2009.03326.x. Epub 2009 Feb 24.

17.

Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.

Reeves D, Liu CY.

J Oncol Pharm Pract. 2010 Mar;16(1):27-31. doi: 10.1177/1078155209104379. Epub 2009 Apr 28.

PMID:
19401307
18.

Survival in patients with malignancy and venous thromboembolism by tumour subtype and thrombus location.

Prestidge T, Lee S, Harper P, Young L, Ockelford P.

Intern Med J. 2012 Jan;42(1):71-4. doi: 10.1111/j.1445-5994.2010.02401.x.

PMID:
21118408
19.

Epidemiology of cancer-related venous thromboembolism.

Wun T, White RH.

Best Pract Res Clin Haematol. 2009 Mar;22(1):9-23. doi: 10.1016/j.beha.2008.12.001. Review.

20.

Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry.

Trujillo-Santos J, Prandoni P, Rivron-Guillot K, Román P, Sánchez R, Tiberio G, Monreal M; RIETE Investigators.

J Thromb Haemost. 2008 Feb;6(2):251-5. Epub 2007 Nov 15.

Supplemental Content

Support Center